Mandibular FracturesPhase 3NCT02081885
Tricalcium Phosphate and Chitosan as Bone Regenerator Versus Autologous Graft in Surgery for Mandibular Fracture
A Phase 3 study testing Tricalcium Phosphate / Chitosan and Autologous Graft in people with Mandibular Fractures, run by Instituto Mexicano del Seguro Social at 1 site in Mexico.
Trial summary
Introduction After a mandibular fracture where bone has been lost, a number of complications and challenges are presented in trying to solve them. These defects are mainly classified into two groups: functional and cosmetic. Read more about this study
- Who is it for?
- Ages 18 to 45 years
- Conditions the study is for
- Mandibular Fractures
- What is being tested?
- Tricalcium Phosphate / Chitosan and Autologous Graft
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteMexico
- Study dates
- Jan 2014to Jan 2017
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients ot the service of reconstructive and plastic surgery of the Civil Hospital in Guadalajara Fray Antonio Mayor, with a diagnosis of traumatic mandibular fracture with bone defect < 2.5 cm.
- Wishing to participate in the study
Who cannot join
- Patients who have undergone radiation therapy.
- Psychiatric Patients.
- Patients who have not signed informed consent.
- Patients with Diabetes
- Patients with alterations in bone metabolism
- Patients with kidney diseases
- Patients who receipt corticosteroids
- Patients with heart disease
Trial locations and contacts
1 site in 1 country.
Mexico1 site
Civil Hospital of Guadalajara Fray Antonio Alcalde
Guadalajara, Jalisco, 44280
About this study
Official title: Therapeutic Efficacy of Tricalcium Phosphate and Chitosan as Bone Regenerator Versus Autologous Graft in Surgery for Mandibular Fracture
Introduction After a mandibular fracture where bone has been lost, a number of complications and challenges are presented in trying to solve them. These defects are mainly classified into two groups: functional and cosmetic. The functional defects are incompetence of the lower lip, salivary incontinence, severe difficulty chewing and swallowing, temporomandibular joint disorders and difficulty in pronouncing words.
Esthetically facial asymmetry is produced with collapse of the affected side. Unreconstructed jaw retrusion and tends to offset the affected side, there is a change in mandibular movements, which, previous vertical movements are replaced by oblique or diagonal movements controlled by a single temporomandibular joint. It also presents a limitation in motility and lingual force, besides proprioception disorder left by the inferior alveolar nerve The loss of bone in mandibular fractures, is one of the great challenges facing maxillofacial surgery and unfortunately increasingly common. That's why they have done and are still doing research for the development of biomaterials, all with the purpose of trying to solve this problem by offering the patient better results than those obtained in the past, restoring both function and facial aesthetics according to each case
Read the detailed description
Objective To evaluate the therapeutic efficacy of the combination of tricalcium phosphate and chitosan in comparison with autologous bone graft in bone regeneration applied to surgical mandibular fracture
Material and Methods Type of Study: Clinical Trial (Randomized) controlled This project will be performed in patients from the Service of Plastic and Reconstructive Surgery, Maxillofacial, Civil Hospital of Guadalajara Fray Antonio Alcalde diagnosed with facial fractures Computed tomography imaging study with axial and coronal skull, as well as three-dimensional reconstruction was performed, to obtain the size of the bone defect
Procedure A compound, with 5 grams of chitosan in an acidic solution, consisting of 2 ml acetic acid 99% water, is prepared. Leaving it under constant stirring for over 12 hours to obtain a chitosan acidic gel. The total volume of compound of chitosan will be doubly filtered to remove impurities and microorganisms that may contaminate the solution. The first filtration was carried out with Whatman paper No. 1 to remove residual impurities and the second whit nitrocellulose filter of 0.45 microns to ensure complete removal of bacteria and impurities. Once filtered, the chitosan compound be mixed with 0.2 g of tricalcium phosphate gauge and dispensed in 15-20ml in petri dishes and incubated at dry heat stove at 40 ° C for 16 hours or until completely evaporate the liquid phase, dehydration of the compound obtained in a thin film. The films of tricalcium phosphate and chitosan will be neutralized with 0.5% NaOH until evolution of the petri dish and then washed thoroughly with distilled water to remove traces of NaOH 0.5%. The film neutralized will be placed in a container for shape and incubated for 2 hours at 50 °C for drying. Subsequently, the films will be trimmed and sterilized in ultraviolet imager for 15 minutes and then sealed in packages of manufacturing list for your own use.
Description of the technical surgical To the patients selected for the protocol will be following the next described procedure; Under general inhaled anesthesia naso-tracheal via, we will proceed to clean with an adequate asepsis and antisepsis intraoral and face technique, sterile fields will be placed on a regular basis, and they will be infiltrate with lidocaine and epinephrine on the incision line depending on the type of approach. After this they will be incision in the skin and subcutaneous tissue, subsequently, with blunt dissection in deep planes, dissection of superficial cervical fascia and muscle platysma neck, until find the fracture traces in the jaw bone (depending on the classification on the anatomic localization). There will be a reduction of the fracture with manual traction, and placing a rigid bone fixation with plates and screws of titanium, and at the same time using cooling steril physiological solution to avoid overheating of the bone (at this moment the surgical process is identical in the two groups) after the end of this process and have a strong jaw, is then replaced the missing bone segment, the group with autologous graft from the iliac crest, where will be oblique incision with guidance bottom and back to the iliac crest, 1 cm from the back of the spine and approximate length of 5 cm, previous insertions of the abdominal muscles and external oblique Internal, until reach the periosteum.
The results package- lateral femoral cutaneous nerve and the lateral femoral cutaneous nerve are the only structures that must not be damaged during the dissection.
A court is performed with an osteotome behind, approximately 2 cm from the edge of the ridge, producing a fracture of the cortical leaving exposed the cancellous bone. The tables are transected bone, by means of an osteotome behind, in order to obtain a type of cortical graft-medullary, with a diameter no greater than 2.5 cm, the bleeding will be assessed and if necessary materials shall be used hemostatic, finally, it was sewn by planes with vicryl 000 and skin with nylon in 0000 to the end will be placed sterile dressing.
In the case of patients who are included in the group of the biomaterial composed of tricalcium phosphate and chitosan previously obtained in the laboratory and sterilized, will come in predetermined diameter of 2.5 x 2.5 cm. This will be clipped and adapted to the bone defect allowing intimate contact between the bone and the biomaterial.
When the intervention has been made (autologous graft or biomaterial), the incision will be approached by planes with vicryl 000 and at the skin with Nylon 000 sub dermal continued suture. At the end a sterile bandage is going to be placed and the surgery will be completed.
Statistical Analysis Nominal variables were analyzed using percentage frequencies, X2 test or Fisher exact test. Numeric variables using Student's t test for independent samples and ANOVA with post hoc Scheffe test. U Mann Whitney and Kruskal Wallis tests will be used as long as data do not conform to normal distribution. All values of p <0.05 was considered statistically significant. The analysis is going to do by using the SPSS v 17 for Windows program.
- Conditions
- Mandibular Fractures
- Being tested
- Tricalcium Phosphate / Chitosan, Autologous Graft
- Keywords
- Tricalcium phosphate, Chitosan, Grafting, Bone, Mandibular Fractures
- Medical subject headings
- Mandibular Fractures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tricalcium Phosphate / ChitosanProcedure or surgery
Autologous GraftProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| Tricalcium Phosphate / Chitosan | Experimental | Not described Receives: Procedure: Tricalcium Phosphate / Chitosan |
| Autologous Graft | Active comparator | Not described Receives: Procedure: Autologous Graft |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bone density determination in regenerated bone.
Determined with computed tomography measure by using Hounsfield Units.
Measured: 30 days after the procedure.
Bone density determination in regenerated bone.
Determined with computed tomography measure by using Hounsfield Units.
Measured: 6 months after the procedure.
Secondary outcomes (11)
Classification of mandibular fracture
They will be classified as Nasal, Maxilla-malar, Dentoalveolar, Mandibular and Lefort fracture.
Measured: One day before surgery
Edema
Identifying the presence or absence of edema.
Measured: Patients will be followed daily from the immediate postoperative period until discharge, an expected average of 3 days.
Postoperative infection.
Identifying the different possible infectious postoperative complications.
Measured: Patients will be followed daily from the immediate postoperative period until discharge, an expected average of 3 days.
Defect Size
According to the millimeters of bone structures missed.
Measured: 30 days after the procedure.
Edema
Identifying the presence or absence of edema.
Measured: 8 days after procedure.
Edema
Identifying the presence or absence of edema.
Measured: 30 days after procedure.
Edema
Identifying the presence or absence of edema.
Measured: 6 months after procedure.
Postoperative infection.
Identifying the different possible infectious postoperative complications.
Measured: 8 days after procedure.
Postoperative infection.
Identifying the different possible infectious postoperative complications.
Measured: 30 days after procedure.
Postoperative infection.
Identifying the different possible infectious postoperative complications.
Measured: 6 months after procedure
Defect Size
According to the millimeters of bone structures missed.
Measured: 6 months after the procedure.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2014 (estimated)
- Study startJan 2014
- Primary completionJan 2015
- Study completionJan 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mandibular FracturesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Instituto Mexicano del Seguro Social
- Sponsor type
- Other government
- Collaborators
- Hospital Civil de Guadalajara
- Responsible party
- Principal investigator, GONZALEZ-OJEDA ALEJANDRO, Instituto Mexicano del Seguro Social
- Investigators
- Alejandro Gonzalez-Ojeda, PhD, Principal investigator, Instituto Mexicano del Seguro Social
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02081885
- Sponsor's protocol ID
- Chitosan-2014-1
- Status last verified
- Sep 2023
- First submitted
- 31 Jan 2014
- Last updated
- 3 Oct 2023
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 3 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Therapeutic Efficacy of Tricalcium Phosphate and Chitosan as Bone Regenerator Versus Autologous Graft in Surgery for Mandibular Fracture
- ClinicalTrials.gov ID
- NCT02081885
- Acronym / sponsor ID
- Chitosan-2014-1
- Conditions
- Mandibular Fractures
- Keywords
- Tricalcium phosphate, Chitosan, Grafting, Bone, Mandibular Fractures
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Instituto Mexicano del Seguro SocialOther government
- Collaborators
- Hospital Civil de Guadalajara
- Study start
- Jan 2014 (actual)
- Primary completion
- Jan 2015 (actual)
- Study completion
- Jan 2017 (actual)
- First posted
- 7 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction After a mandibular fracture where bone has been lost, a number of complications and challenges are presented in trying to solve them. These defects are mainly classified into two groups: functional and cosmetic. The functional defects are incompetence of the lower lip, salivary incontinence, severe difficulty chewing and swallowing, temporomandibular joint disorders and difficulty in pronouncing words.
Esthetically facial asymmetry is produced with collapse of the affected side. Unreconstructed jaw retrusion and tends to offset the affected side, there is a change in mandibular movements, which, previous vertical movements are replaced by oblique or diagonal movements controlled by a single temporomandibular joint. It also presents a limitation in motility and lingual force, besides proprioception disorder left by the inferior alveolar nerve The loss of bone in mandibular fractures, is one of the great challenges facing maxillofacial surgery and unfortunately increasingly common. That's why they have done and are still doing research for the development of biomaterials, all with the purpose of trying to solve this problem by offering the patient better results than those obtained in the past, restoring both function and facial aesthetics according to each case
Detailed description
Objective To evaluate the therapeutic efficacy of the combination of tricalcium phosphate and chitosan in comparison with autologous bone graft in bone regeneration applied to surgical mandibular fracture
Material and Methods Type of Study: Clinical Trial (Randomized) controlled This project will be performed in patients from the Service of Plastic and Reconstructive Surgery, Maxillofacial, Civil Hospital of Guadalajara Fray Antonio Alcalde diagnosed with facial fractures Computed tomography imaging study with axial and coronal skull, as well as three-dimensional reconstruction was performed, to obtain the size of the bone defect
Procedure A compound, with 5 grams of chitosan in an acidic solution, consisting of 2 ml acetic acid 99% water, is prepared. Leaving it under constant stirring for over 12 hours to obtain a chitosan acidic gel. The total volume of compound of chitosan will be doubly filtered to remove impurities and microorganisms that may contaminate the solution. The first filtration was carried out with Whatman paper No. 1 to remove residual impurities and the second whit nitrocellulose filter of 0.45 microns to ensure complete removal of bacteria and impurities. Once filtered, the chitosan compound be mixed with 0.2 g of tricalcium phosphate gauge and dispensed in 15-20ml in petri dishes and incubated at dry heat stove at 40 ° C for 16 hours or until completely evaporate the liquid phase, dehydration of the compound obtained in a thin film. The films of tricalcium phosphate and chitosan will be neutralized with 0.5% NaOH until evolution of the petri dish and then washed thoroughly with distilled water to remove traces of NaOH 0.5%. The film neutralized will be placed in a container for shape and incubated for 2 hours at 50 °C for drying. Subsequently, the films will be trimmed and sterilized in ultraviolet imager for 15 minutes and then sealed in packages of manufacturing list for your own use.
Description of the technical surgical To the patients selected for the protocol will be following the next described procedure; Under general inhaled anesthesia naso-tracheal via, we will proceed to clean with an adequate asepsis and antisepsis intraoral and face technique, sterile fields will be placed on a regular basis, and they will be infiltrate with lidocaine and epinephrine on the incision line depending on the type of approach. After this they will be incision in the skin and subcutaneous tissue, subsequently, with blunt dissection in deep planes, dissection of superficial cervical fascia and muscle platysma neck, until find the fracture traces in the jaw bone (depending on the classification on the anatomic localization). There will be a reduction of the fracture with manual traction, and placing a rigid bone fixation with plates and screws of titanium, and at the same time using cooling steril physiological solution to avoid overheating of the bone (at this moment the surgical process is identical in the two groups) after the end of this process and have a strong jaw, is then replaced the missing bone segment, the group with autologous graft from the iliac crest, where will be oblique incision with guidance bottom and back to the iliac crest, 1 cm from the back of the spine and approximate length of 5 cm, previous insertions of the abdominal muscles and external oblique Internal, until reach the periosteum.
The results package- lateral femoral cutaneous nerve and the lateral femoral cutaneous nerve are the only structures that must not be damaged during the dissection.
A court is performed with an osteotome behind, approximately 2 cm from the edge of the ridge, producing a fracture of the cortical leaving exposed the cancellous bone. The tables are transected bone, by means of an osteotome behind, in order to obtain a type of cortical graft-medullary, with a diameter no greater than 2.5 cm, the bleeding will be assessed and if necessary materials shall be used hemostatic, finally, it was sewn by planes with vicryl 000 and skin with nylon in 0000 to the end will be placed sterile dressing.
In the case of patients who are included in the group of the biomaterial composed of tricalcium phosphate and chitosan previously obtained in the laboratory and sterilized, will come in predetermined diameter of 2.5 x 2.5 cm. This will be clipped and adapted to the bone defect allowing intimate contact between the bone and the biomaterial.
When the intervention has been made (autologous graft or biomaterial), the incision will be approached by planes with vicryl 000 and at the skin with Nylon 000 sub dermal continued suture. At the end a sterile bandage is going to be placed and the surgery will be completed.
Statistical Analysis Nominal variables were analyzed using percentage frequencies, X2 test or Fisher exact test. Numeric variables using Student's t test for independent samples and ANOVA with post hoc Scheffe test. U Mann Whitney and Kruskal Wallis tests will be used as long as data do not conform to normal distribution. All values of p <0.05 was considered statistically significant. The analysis is going to do by using the SPSS v 17 for Windows program.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Tricalcium Phosphate / Chitosan | Experimental | Procedure: Tricalcium Phosphate / Chitosan |
| Autologous Graft | Active comparator | Procedure: Autologous Graft |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Patients ot the service of reconstructive and plastic surgery of the Civil Hospital in Guadalajara Fray Antonio Mayor, with a diagnosis of traumatic mandibular fracture with bone defect < 2.5 cm.
- Wishing to participate in the study
Key exclusion criteria (8 listed)
- Patients who have undergone radiation therapy.
- Psychiatric Patients.
- Patients who have not signed informed consent.
- Patients with Diabetes
- Patients with alterations in bone metabolism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tricalcium Phosphate / Chitosan | Procedure or surgery | Tricalcium Phosphate / Chitosan |
| Autologous Graft | Procedure or surgery | Autologous Graft |
Primary outcome
Bone density determination in regenerated bone.
Time frame: 30 days after the procedure.
Determined with computed tomography measure by using Hounsfield Units.
Bone density determination in regenerated bone.
Time frame: 6 months after the procedure.
Determined with computed tomography measure by using Hounsfield Units.
11 secondary outcomes
Classification of mandibular fracture
Time frame: One day before surgery
Edema
Time frame: Patients will be followed daily from the immediate postoperative period until discharge, an expected average of 3 days.
Postoperative infection.
Time frame: Patients will be followed daily from the immediate postoperative period until discharge, an expected average of 3 days.
Defect Size
Time frame: 30 days after the procedure.
Edema
Time frame: 8 days after procedure.
Edema
Time frame: 30 days after procedure.
Edema
Time frame: 6 months after procedure.
Postoperative infection.
Time frame: 8 days after procedure.
Postoperative infection.
Time frame: 30 days after procedure.
Postoperative infection.
Time frame: 6 months after procedure
Defect Size
Time frame: 6 months after the procedure.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Oct 2023.
Related trials for Mandibular Fractures
Recruiting
Optimized Osteosynthesis: Bone Mineral Density Recovery in Mandibular Body Fractures Using Patient-Specific Versus Conventional Plates
Mandibular Fractures
Not yet recruiting
Clinical And Radiographic Assessment of H-shaped Bone Plates in Management of Body and Angle Mandibular Fractures
Mandibular Angle Fractures, Mandibular Body Fractures
Active, not recruiting
Fixation of Mandibular Angle Fracture Using 3D Titanium Miniplate Versus Standard Two Plate Fixation
Mandible Fracture, Force Measurement
Recruiting
Occlusal Assessment of Pediatric Mandibular Fractures Managed by 3D-Printed Acrylic Occlusal Cap Splint: A Case Series
Pediatric Mandibular Fracture
Recruiting
Custom-Made Titanium Plates Versus Custom-Made Polyether Ether Ketone (PEEK) Plates
Mandibular Fractures
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alejandro Gonzalez-Ojeda, PhD principal investigator
Instituto Mexicano del Seguro Social
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tricalcium Phosphate / Chitosan and Autologous Graft in people with Mandibular Fractures, run by Instituto Mexicano del Seguro Social at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bone density determination in regenerated bone. (time frame: 30 days after the procedure.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2023.